TAMPA, Fla., May 8, 2009 (GLOBE NEWSWIRE) -- Kforce Clinical Research Inc., a provider of clinical trial resourcing solutions and a division of Kforce Inc. (Nasdaq:KFRC), has won the 2008 Pfizer Development Operations' "Strategic Supplier Excellence Award." The annual award recognizes functional service providers that have demonstrated consistent performance in the areas of quality, service delivery and reliability, innovation and business processes and customer service.
"This recognition is the direct result of the efforts and accomplishments of our tremendously talented and dedicated team members," said Randy Kehrmeyer, President of Kforce Clinical Research. "We are driven by a shared belief that we have an opportunity -- and an obligation -- to make a meaningful impact in the lives of our employees, clients and ultimately the countless patients in need of the medicines we are working together to develop."
Kforce Clinical Research managed project deliverables for more than 200 Pfizer studies consistently throughout the year. Applying the principals of Lean Six Sigma, Kforce streamlined business processes across the U.S. and provided Pfizer with a more consultative view into project staffing and overall protocol management. Kforce also instituted a new business model for site selection that has improved study start-up time.
"Kforce has consistently demonstrated superior performance, adding high value to the U.S. clinical operations business," said Mike Collins, Vice President of Clinical Study Operations at Pfizer. "In addition to exceeding expectations across all award categories, Kforce implemented strong business tools and processes that had meaningful impacts supporting our commitment for continuous improvement within Pfizer."
Kforce Clinical Research (www.kforce.com/clinicalresearch) provides customized and flexible functional outsourcing solutions to the biopharmaceutical industry. It specializes in clinical monitoring, site and study management, drug safety, regulatory, clinical data management, data entry, clinical programming and biostatistics. Whereas other outsourcing providers either augment a company's drug trial with people or handle all aspects of the trial, Kforce's functional outsourcing model offers a flexible, tailored approach developed to mirror each company's business model and address specific requirements of the drug trial itself.
About Kforce
Kforce (Nasdaq:KFRC) is a professional staffing firm providing flexible and permanent staffing solutions in the skill areas of technology, finance & accounting, health and life sciences, and government solutions (KGS). Backed by approximately 2,000 staffing specialists, Kforce is committed to "Great People = Great Results" for our valued clients and candidates. Kforce operates with 61 offices in 41 markets in North America and two in the Philippines. For more information, please visit our Web site at http://www.kforce.com/.
The Kforce Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3749
Certain of the above statements contained in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. Factors that could cause actual results to differ materially include the following: business conditions and growth in the staffing industry and general economy; competitive factors, risks due to shifts in the market demand, including, without limitation, shifts in demand for our Technology, Finance and Accounting, Health and Life Sciences and Government Solutions segments, as well as the market for search and flexible staffing assignments; changes in the service mix; ability of the Firm to complete acquisitions; and the risk factors listed from time to time in the Firm's reports filed with the Securities and Exchange Commission, as well as assumptions regarding the foregoing. The words "should," "believe," "estimate," "expect," "intend," "anticipate," "foresee," "plan" and similar expressions and variations thereof identify certain of such forward-looking statements, which speak only as of the dates on which they were made. The Firm undertakes no obligation to publicly update or revise any forward-looking statements. As a result, such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those indicated in the forward-looking statements as a result of various factors. Readers are cautioned not to place undue reliance on these forward-looking statements.